Grufity logoGrufity logo

Supernus Pharmaceuticals Inc Stock Research

SUPN

40.68USD-0.38(-0.93%)Market Closed

Market Summary

USD40.68-0.38
Market Closed
-0.93%

SUPN Alerts

SUPN Stock Price

SUPN RSI Chart

SUPN Valuation

Market Cap

2.2B

Price/Earnings (Trailing)

57.51

Price/Sales (Trailing)

3.29

EV/EBITDA

21.5

Price/Free Cashflow

15.7

SUPN Price/Sales (Trailing)

SUPN Profitability

EBT Margin

4.20%

Return on Equity

4.42%

Return on Assets

2.22%

Free Cashflow Yield

6.37%

SUPN Fundamentals

SUPN Revenue

Revenue (TTM)

659.0M

Revenue Y/Y

19.46%

Revenue Q/Q

4.29%

SUPN Earnings

Earnings (TTM)

37.7M

Earnings Y/Y

-91.89%

Earnings Q/Q

-77.76%

Price Action

52 Week Range

24.9541.70
(Low)(High)

Last 7 days

0.9%

Last 30 days

13.8%

Last 90 days

17%

Trailing 12 Months

40.2%

SUPN Financial Health

Current Ratio

0.91

SUPN Investor Care

Shares Dilution (1Y)

0.13%

Diluted EPS (TTM)

0.64

Peers (Alternatives to Supernus Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
442.1B
96.0B
-4.77% 1.21%
23.08
4.6
5.02% 7.14%
308.1B
29.2B
-6.33% 46.49%
51.07
10.54
5.34% 1.02%
267.0B
59.0B
-5.13% 34.98%
17.49
4.53
27.84% 112.03%
245.5B
99.9B
-13.80% -15.92%
8.25
2.46
45.01% 53.21%
154.0B
46.7B
0.64% 15.96%
23.07
3.3
2.79% 223.53%
MID-CAP
5.0B
4.4B
10.03% -0.57%
-46.66
1.14
1.80% 57.67%
2.2B
659.0M
13.79% 40.18%
57.51
3.29
16.78% -53.92%
SMALL-CAP
1.9B
613.6M
24.42% -38.51%
-3.79
3.14
37.73% -7.19%
1.6B
3.1M
23.90% 79.89%
-5.08
503.44
-77.09% -12.24%
1.4B
-
33.79% -57.23%
-0.46
1.95
-4.11% -144.36%
1.2B
23.5M
12.85% 73.07%
-14.2
49.6
243.57% -1.04%
942.1M
112.7M
- -24.55%
-4.21
8.36
45.53% 40.26%
885.5M
-
-2.61% -19.99%
2.65
2.34
10.49% -16.07%
298.8M
49.7M
46.97% -25.95%
-5.03
6.01
28.95% 32.80%
94.1M
2.6B
-43.99% -88.43%
-0.03
0.04
-13.88% -4855.92%

Financials for Supernus Pharmaceuticals

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue4.6%659630601580564
  S&GA Expenses11.0%405365334305260
  R&D Expenses-0.1%7878779087
Costs and Expenses10.9%641578527494441
EBITDA-16.2%96114108108-
EBITDA Margin-19.9%0.15*0.18*0.18*0.19*-
Earnings Before Taxes-51.5%28577773111
EBT Margin-53.7%0.04*0.09*0.13*0.13*-
Interest Expenses-79.3%-9.50-5.30-1.6432
Net Income-34.5%3857735382
Net Income Margin-37.3%0.06*0.09*0.12*0.09*-
Free Cahsflow14.9%13812093125-
* denotes actual numbers (not divided by Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-0.1%1,6931,6951,6401,6891,555
  Current Assets6.2%664625569602668
    Cash Equivalents-35.7%111173116203215
  Inventory-2.0%8385898660
  Net PPE1.5%1717---
  Goodwill1.7%11711511511840
Liabilities-1.5%840854811873745
  Current Liabilities-1.3%726736285315235
    LT Debt, Current0.1%401401---
    LT Debt, Non CurrentNaN%--379--
Shareholder's Equity1.4%853841828816810
  Retained Earnings0.4%456454446380377
  Additional Paid-In Capital2.9%401390383434429
Accumulated Depreciation6.0%13121216-
Shares Outstanding0%5353535353
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations14.9%13812095127110
  Share Based Compensation5.8%1716181817
Cashflow From Investing-502.2%-91.77-15.24-80.45-81.91-108.70
Cashflow From Financing3.3%-150.05-155.18-154.70-130.429

Risks for SUPN

What is the probability of a big loss on SUPN?

100%


Probability that Supernus Pharmaceuticals stock will be more than 20% underwater in next one year

45%


Probability that Supernus Pharmaceuticals stock will be more than 30% underwater in next one year.

38.1%


Probability that Supernus Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does SUPN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Supernus Pharmaceuticals was unfortunately bought at previous high price.

Drawdowns

Returns for SUPN

Cumulative Returns on SUPN

18.4%


10-Year Cumulative Returns

20.0%


7-Year Cumulative Returns

-0.4%


5-Year Cumulative Returns

19.6%


3-Year Cumulative Returns

What are the long-term rolling returns for SUPN?

FIve years rolling returns for Supernus Pharmaceuticals.

Annualized Returns

Which funds bought or sold SUPN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-01-26
Empowered Funds, LLC
new
-
1,680,000
1,680,000
0.11%
2023-01-26
State of Tennessee, Treasury Department
added
12.01
252,000
1,064,000
-%
2023-01-26
Stephens Investment Management Group LLC
reduced
-0.06
3,222,000
57,579,000
1.04%
2023-01-26
OREGON PUBLIC EMPLOYEES RETIREMENT FUND
reduced
-0.17
30,899
627,899
0.01%
2023-01-26
STRS OHIO
unchanged
-
1,000
28,000
-%
2023-01-26
Eagle Bay Advisors LLC
added
19.28
22,645
113,645
0.06%
2023-01-26
COMERICA BANK
reduced
-21.53
-102,000
1,303,000
0.01%
2023-01-26
CAMPBELL NEWMAN ASSET MANAGEMENT INC
added
3.26
72,925
894,925
0.09%
2023-01-25
Bridge City Capital, LLC
reduced
-0.71
100,000
2,248,000
1.15%
2023-01-25
Mayflower Financial Advisors, LLC
unchanged
-
563
24,563
-%

1–10 of 46

Latest Funds Activity

Are funds buying SUPN calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own SUPN
No. of Funds

Supernus Pharmaceuticals News

MarketBeat

Duality Advisers LP Invests $300000 in Supernus Pharmaceuticals ....

MarketBeat,
43 hours ago

ETF Daily News

Investor's Business Daily

Benzinga

Schedule 13G FIlings of Supernus Pharmaceuticals

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jan 23, 2023
blackrock inc.
17.8%
9,604,073
SC 13G/A
Feb 15, 2022
armistice capital, llc
7.8%
4,136,000
SC 13G/A
Jan 27, 2022
blackrock inc.
15.9%
8,451,022
SC 13G/A
Jan 26, 2022
blackrock inc.
15.9%
8,451,022
SC 13G/A
Feb 16, 2021
armistice capital, llc
5.9%
3,120,000
SC 13G/A
Feb 10, 2021
vanguard group inc
10.06%
5,298,078
SC 13G/A
Jan 25, 2021
blackrock inc.
16.9%
8,912,801
SC 13G
Mar 12, 2020
armistice capital, llc
5.5%
2,888,000
SC 13G
Feb 12, 2020
vanguard group inc
10.11%
5,305,889
SC 13G/A
Feb 10, 2020
blackrock inc.
16.6%
8,734,832
SC 13G/A

SUPN Fair Value

Recent SEC filings of Supernus Pharmaceuticals

View All Filings
Date Filed Form Type Document
Jan 23, 2023
SC 13G/A
Major Ownership Report
Jan 20, 2023
4
Insider Trading
Jan 19, 2023
4
Insider Trading
Jan 19, 2023
4
Insider Trading
Jan 17, 2023
4
Insider Trading
Jan 17, 2023
4
Insider Trading
Jan 17, 2023
4
Insider Trading
Jan 13, 2023
4/A
Insider Trading
Jan 13, 2023
4/A
Insider Trading
Jan 12, 2023
4
Insider Trading

Latest Insider Trading transactions for SUPN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-01-18
Khattar Jack A.
acquired
77,244.8
9.56
8,080
president, ceo
2023-01-18
Khattar Jack A.
sold
-199,394
40.3959
-4,936
president, ceo
2023-01-17
Bhatt Padmanabh P.
acquired
44,061.4
9.13
4,826
sr. vp of ip, cso
2023-01-17
Khattar Jack A.
acquired
400,755
9.56
41,920
president, ceo
2023-01-17
Bhatt Padmanabh P.
sold
-192,638
39.9167
-4,826
sr. vp of ip, cso
2023-01-17
Khattar Jack A.
sold
-1,018,730
40.0349
-25,446
president, ceo
2023-01-10
Hudson Frederick M.
acquired
68,903.8
7.9
8,722
-
2023-01-06
Bhatt Padmanabh P.
acquired
1,588.62
9.13
174
sr. vp of ip, cso
2023-01-06
Bhatt Padmanabh P.
sold
-6,942.6
39.9
-174
sr. vp of ip, cso
2022-12-28
NEWHALL CHARLES W III
acquired
206,711
7.9
26,166
-

1–10 of 50

Jack A. Khattar
580
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

SUPN Income Statement

2022-09-30
Condensed Consolidated Statements of Earnings - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues    
Total revenues$ 177,353$ 148,464$ 499,910$ 420,725
Costs and expenses    
Cost of goods sold[1]25,87818,08564,26758,067
Research and development19,55419,65456,77869,389
Selling, general and administrative112,31472,032303,249203,024
Amortization of intangible assets20,6446,00961,93217,964
Contingent consideration expense (gain)486801,894(7,650)
Total costs and expenses178,876115,860488,120340,794
Operating earnings (loss)(1,523)32,60411,79079,931
Other income (expense)    
Interest expense(1,724)(5,925)(5,476)(17,489)
Interest and other income, net2,8032,28119,2898,682
Total other income (expense)1,079(3,644)13,813(8,807)
Earnings (Loss) before income taxes(444)28,96025,60371,124
Income tax (benefit) expense(2,193)7,398(9,627)20,142
Net earnings$ 1,749$ 21,562$ 35,230$ 50,982
Earnings per share    
Basic (in dollars per share)$ 0.03$ 0.41$ 0.66$ 0.96
Diluted (in dollars per share)$ 0.03$ 0.40$ 0.62$ 0.94
Weighted average shares outstanding    
Basic (in shares)53,789,67453,187,76453,517,83853,053,441
Diluted (in shares)55,034,83854,334,79461,543,12154,301,461
Net product sales    
Revenues    
Total revenues$ 172,724$ 145,532$ 485,647$ 412,541
Royalty revenues    
Revenues    
Total revenues$ 4,629$ 2,932$ 14,263$ 8,184
[1]Excludes amortization of acquired intangible assets

SUPN Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets  
Cash and cash equivalents$ 111,492$ 203,434
Marketable securities280,297136,246
Accounts receivable, net164,086148,932
Inventories, net83,16585,959
Prepaid expenses and other current assets24,84627,019
Total current assets663,886601,590
Long-term marketable securities131,937119,166
Property and equipment, net15,87216,955
Intangible assets, net722,761784,693
Goodwill117,383117,516
Other assets41,29049,232
Total assets1,693,1291,689,152
Current liabilities  
Accounts payable and accrued liabilities110,302117,683
Accrued product returns and rebates158,470132,724
Contingent consideration, current portion47,59044,840
Convertible notes, net401,4380
Other current liabilities8,18720,132
Total current liabilities725,987315,379
Convertible notes, net0379,252
Contingent consideration, long-term9,78135,637
Operating lease liabilities, long-term36,02841,298
Deferred income tax liabilities58,16485,355
Other liabilities10,37116,380
Total liabilities840,331873,301
Stockholders’ equity  
Common Stock, Value, Issued5453
Additional paid-in capital401,026434,337
Accumulated other comprehensive earnings (loss), net of tax(4,046)1,539
Retained earnings455,764379,922
Total stockholders’ equity852,798815,851
Total liabilities and stockholders’ equity$ 1,693,129$ 1,689,152